Tobramycin in the treatment of severe and complicated urinary tract infections.
Tobramycin is a new aminoglycoside antibiotic with pharmacological similarities to gentamicin. Eleven of 15 patients with a severe or complicated gram-negative urinary tract infection were cured by treatment with a five day course of tobramycin. No side effects were noted. This drug should prove beneficial for the treatment of severe gram-negative sepsis and promises to be particularly valuable for infections due to Pseudomonas aeruginosa and organisms resistant to gentamicin.
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D004352:Drug Resistance, Microbial; D005260:Female; D005839:Gentamicins / Q000494:pharmacology; D006801:Humans; D007674:Kidney Diseases / Q000150:complications; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa; D014031:Tobramycin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D014031:Tobramycin